Skip to main content
SpringerLink
Log in

Multimodalität von Vorteil

Behandlung des kleinzelligen Lungenkarzinoms

  • Zertifizierte Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Zusammenfassung

Das kleinzellige Lungenkarzinom ist hochaggressiv und die Betroffenen haben eine schlechte Prognose. Gleichzeitig ist der Tumor aber relativ chemosensibel. Am besten sind die Therapieergebnisse unter einem multimodalen Behandlungskonzept, etwa einer Chemotherapie plus Strahlentherapie oder Operation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Goeckenjan G et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. AWMF-Registernummer 020 - 007

  2. Lad T et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest. 1994;106(6 Suppl):320S–323S.

    Article  CAS  PubMed  Google Scholar 

  3. Weksler B et al. Surgical resection should be considered for stage I and II small cell carcinoma of the lung. Ann Thorac Surg. 2012;94(3):889–93.

    Article  PubMed  Google Scholar 

  4. Takei H et al. Surgery for small cell lung cancer: a retrospective analysis of 243 patients from Japanese Lung Cancer Registry in 2004. J Thorac Oncol. 2014;9(8):1140–5.

    Article  PubMed  Google Scholar 

  5. Fried DB et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22(23):4837–45.

    Article  PubMed  Google Scholar 

  6. Schuette W. Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer. 2001;33(1, Suppl):S99–107.

    Article  PubMed  Google Scholar 

  7. Takada M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20(14):3054–60.

    Article  CAS  PubMed  Google Scholar 

  8. Meert AP et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer. 2001;1:5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Skarlos DV et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol. 1994;5(7):601–7.

    CAS  PubMed  Google Scholar 

  10. de Jong WK et al. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. Eur J Cancer. 2007;43(16):2345–50.

    Article  PubMed  Google Scholar 

  11. Jeremic B et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol. 1999;17(7):2092–9.

    CAS  PubMed  Google Scholar 

  12. Slotman BJ et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42.

    Article  PubMed  Google Scholar 

  13. Slotman B et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–72.

    Article  CAS  PubMed  Google Scholar 

  14. Seto T et al. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. J Clin Oncol 32(5s, Suppl):Abstr 7503.

  15. Rudin CM et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008;26(6):870–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Lee SM et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009;101(15):1049–57.

    Article  CAS  PubMed  Google Scholar 

  17. Göttinger SN et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. J Clin Oncol. 2015;33(supply):Abstr 8025.

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II, Krankenhaus Martha-Maria Halle-Dölau, Röntgenstraße 1, 06120, Halle (Saale), Deutschland

    Wolfgang Schütte

Authors
  1. Wolfgang Schütte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Schütte.

Additional information

Interessenkonflikt

Der Autor erklärt, dass er sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließ und dass keine potenziellen Interessenkonflikte vorliegen. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schütte, W. Behandlung des kleinzelligen Lungenkarzinoms. Im Focus Onkologie 19, 50–55 (2016). https://doi.org/10.1007/s15015-016-2278-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-016-2278-7

Search

Navigation